[Rheumatoid arthritis]

Nihon Rinsho. 2005 May:63 Suppl 5:261-6.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / etiology
  • Arthritis, Rheumatoid* / physiopathology
  • Arthritis, Rheumatoid* / therapy
  • Autoantibodies / blood
  • Autoimmunity
  • Biomarkers / blood
  • Etanercept
  • Glucose-6-Phosphate Isomerase / immunology
  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Matrix Metalloproteinase 3 / blood
  • Peptides, Cyclic / immunology
  • Prognosis
  • Protein-Tyrosine Kinases
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Rituximab
  • Severity of Illness Index
  • ZAP-70 Protein-Tyrosine Kinase

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Autoantibodies
  • Biomarkers
  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • Immunoglobulin G
  • Peptides, Cyclic
  • Receptors, Tumor Necrosis Factor
  • cyclic citrullinated peptide
  • Rituximab
  • Infliximab
  • Protein-Tyrosine Kinases
  • ZAP-70 Protein-Tyrosine Kinase
  • ZAP70 protein, human
  • Matrix Metalloproteinase 3
  • Glucose-6-Phosphate Isomerase
  • Etanercept